Ruigang G. Cai
Chinese Academy Of Medical Sciences And Peking Union Medical College
Beijing, China
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 71 publications
Overall Survival With Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer: A Single-Center Pooled Analysis.
Journal: Thoracic cancer
Published: April 12, 2026
Prognostic value of Ki-67 index in malignant phyllodes tumor of the breast: a multi-center real-world study.
Journal: Breast cancer research : BCR
Published: October 27, 2025
Trastuzumab and pertuzumab plus carboplatin-based neoadjuvant therapy for HER2-positive breast cancer: a prospective cohort study with integrated genomic and transcriptomic biomarker analysis.
Journal: Therapeutic advances in medical oncology
Published: August 12, 2025
Pathologic complete response after neoadjuvant chemotherapy for HER-2 negative breast cancer with HRR mutation.
Journal: Future oncology (London, England)
Published: July 21, 2025
Associations between dynamic hematological indicators and outcomes in HR-positive, HER2-negative metastatic breast cancer treated with bireociclib or placebo plus fulvestrant: Findings from the BRIGHT-2 trial.
Journal: Breast (Edinburgh, Scotland)
Published: June 27, 2025
Comparison of the efficacy, safety, and cost-effectiveness of trastuzumab biosimilar HLX02 and the originator combined with pertuzumab and chemotherapy in the neoadjuvant treatment of patients with HER-2-positive breast cancer
Journal: Zhonghua zhong liu za zhi [Chinese journal of oncology]
Published: June 19, 2025
Clinicopathological Factors That Predict Different Responses of Breast and Axillary Tumors to Neoadjuvant Chemotherapy and Prognosis Among Patients With Node-Positive Breast Cancer: Real World Data.
Journal: Thoracic cancer
Published: October 27, 2024
The ideal strategies of antibody‒drug conjugate sequential treatment in HER2-expressing metastatic breast cancer: A multi-center real-world study.
Journal: Breast (Edinburgh, Scotland)
Published: October 23, 2024
Molecular Characteristics of Prognosis and Chemotherapy Response in Breast Cancer: Biomarker Identification Based on Gene Mutations and Pathway.
Journal: Journal of breast cancer
Published: July 31, 2024
Pyrotinib combined with metronomic etoposide in heavily pretreated HER2-positive metastatic breast cancer: a single-arm, phase II study.
Journal: BMC cancer
Published: March 25, 2024
Inetetamab-based therapy in real-world treatment patterns with HER2-positive advanced breast cancer patients: a retrospective single-center study.
Journal: Therapeutic advances in medical oncology
Published: February 25, 2024
Dose-dense paclitaxel plus carboplatin in combination with trastuzumab neoadjuvant versus standard adjuvant therapy in human epidermal growth factor receptor-2 positive and hormone receptor negative breast cancer: a prospective cohort study
Journal: Zhonghua zhong liu za zhi [Chinese journal of oncology]
Published: August 14, 2023
Last Updated: 09/26/2026